UCB’s BIMZELX Shows Sustained Three-Year Efficacy in Inflammatory Conditions
UCB has unveiled compelling new three-year data from its phase 3 clinical trials and open-label extensions investigating BIMZELX® (bimekizumab) in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), reinforcing its potential as a long-term treatment option for chronic inflammatory conditions.
The results, presented at the European Congress of Rheumatology (EULAR) 2025, demonstrate consistent and durable control of inflammation, coupled with significant improvements in symptom relief and physical function across patient populations.
Sustained Relief for Psoriatic Arthritis Patients
In patients with psoriatic arthritis, the trials highlighted encouraging results for both biologic-naïve individuals and those previously unresponsive to tumour necrosis factor inhibitors (TNFi).
Notably, 53.2% of biologic-naïve patients and 55.2% of those with a prior inadequate response to TNFi achieved ACR50 – a measure of 50% improvement in disease activity – at the three-year mark.
Crucially, swollen joints were eliminated in nearly 60% of patients, and approximately half achieved minimal disease activity, showcasing robust inflammation control.
A professor from Sorbonne University Hospital praised the consistency of these outcomes across both treatment-naïve and experienced cohorts, stating that these bimekizumab data are notable for their consistency and potential to meet the real-world needs of psoriatic arthritis patients.
Long-Term Efficacy in Axial Spondyloarthritis
For patients with axial spondyloarthritis, bimekizumab demonstrated long-term efficacy across both non-radiographic (nr-axSpA) and radiographic (r-axSpA) forms of the disease.
After three years of treatment, 60.4% of patients with nr-axSpA and 60.1% with r-axSpA achieved ASAS40 – a 40% improvement in key disease indicators. Furthermore, low disease activity, as measured by the Ankylosing Spondylitis Disease Activity Score (ASDAS), was sustained by 61.8% and 59.9% of patients, respectively.
A professor from Ruhr University Bochum emphasised the significance of these results, remarking that these endpoints are key indicators of durable inflammation control in axial spondyloarthritis and underscore the potential of bimekizumab as a long-term therapy.
A Targeted Approach to Inflammation
Bimekizumab stands out as the first and only approved treatment that selectively inhibits both interleukin-17A (IL-17A) and interleukin-17F (IL-17F) – two cytokines that play central roles in driving inflammation.
By targeting both pathways, bimekizumab offers a novel mechanism of action that contributes to its strong and sustained clinical outcomes.
The new data presented at EULAR 2025 adds to a growing body of evidence supporting the use of bimekizumab as a reliable option for those living with PsA and axSpA. UCB continues to advance innovation in rheumatology, with ongoing phase 3 studies in both indications and further research presented at the congress.
Conclusion
With these latest three-year results, UCB’s BIMZELX (bimekizumab) reaffirms its role as a promising and durable treatment for psoriatic arthritis and axial spondyloarthritis. The data speaks not only to its sustained efficacy and inflammation control but also to its potential to improve long-term quality of life for patients – regardless of prior treatment history.
As UCB continues to push forward with further studies and innovation in rheumatology, BIMZELX stands poised to remain at the forefront of care in chronic inflammatory diseases.
News Credits: Bimekizumab shows lasting efficacy at EULAR 2025
Things you may also like: